Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Immunotherapy, a new therapeutic area to destroy tumor cells

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

31 Oct 2009

sanofi-aventis reports financial results for the third quarter of 2009

In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.

30 Oct 2009

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.

30 Oct 2009

Helper T cell's effect raises possibility of cellular therapy and vaccine development

A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal Immunity.

30 Oct 2009

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

TomoTherapy Incorporated announced today that several clinical presentations at the American Society for Radiation Oncology's 51st ASTRO Annual Meeting -- November 1-5, 2009 in Chicago -- will showcase the use of the TomoTherapy® radiation therapy platform as a vital component in the combined modality approach to treating cancer.

30 Oct 2009

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.

29 Oct 2009

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Sangamo BioSciences, Inc. announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells.

29 Oct 2009

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.

29 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

In trying to better predict a patient's response to chemotherapy for cancer treatment, a team of investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, has identified a way to better manipulate a gene product to cause cancer cells to die.

28 Oct 2009

Researchers find healthy dose of exercise good for lymphoma patients receiving chemotherapy

A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found.

28 Oct 2009

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

Building on the strengths of two institutions separated by nearly 9,000 miles over two continents - both renowned in their work in the fight against cancer - the United States Agency for International Development has awarded a $500,000 grant to Fred Hutchinson Cancer Research Center to aid in the construction of the first American cancer clinic and medical-training facility in Africa.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Fred Hutchinson Cancer Research Center receives a $500,000 grant to construct cancer clinic in Africa

27 Oct 2009

Dartmouth explores glucorticoid side effects on bladder-cancer patients

In her most recent study of possible triggers of cancer among northern New England residents, Dartmouth epidemiologist Margaret R. Karagas, Ph.D., and her team identified an enhanced risk to the bladders of patients taking drugs that suppress the immune system.

27 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Professor Suzanne Cory receives award for her work in cancer and immunogenetics

Professor Suzanne Cory, the former director of the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has been named the recipient of the 2009 Pearl Meister Greengard Prize.

24 Oct 2009

FDA issues emergency use authorization for peramivir anti-viral drug

BioCryst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigational anti-viral drug intravenous (i.v.) peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

Seattle Genetics reports its third-quarter financial results

Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.

24 Oct 2009

Lymphoma News and Research

Further Reading

Immunotherapy, a new therapeutic area to destroy tumor cells

sanofi-aventis reports financial results for the third quarter of 2009

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Helper T cell's effect raises possibility of cellular therapy and vaccine development

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

Researchers find healthy dose of exercise good for lymphoma patients receiving chemotherapy

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Fred Hutchinson Cancer Research Center receives a $500,000 grant to construct cancer clinic in Africa

Dartmouth explores glucorticoid side effects on bladder-cancer patients

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Professor Suzanne Cory receives award for her work in cancer and immunogenetics

FDA issues emergency use authorization for peramivir anti-viral drug

Seattle Genetics reports its third-quarter financial results

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News